Oxford Genetics

Oxford Genetics

Oxford Genetics is a synthetic biology company specializing in DNA design, protein expression optimization and cell line development technologies and services.

All edits

Edits on 18 Feb, 2021
Golden AI"prospector:157:88146"
Golden AI edited on 18 Feb, 2021
Edits made to:
Infobox (+3 properties)
Infobox
Legal name
Oxford Genetics Ltd.
Industry
Genetics
Legal classification
Limited company
Edits on 6 Oct, 2020
Golden AI"Funding autocalculation"
Golden AI edited on 6 Oct, 2020
Edits made to:
Infobox (+1 properties)
Infobox
Latest funding round date
March 28, 2019
Edits on 4 Aug, 2020
Aleksander Holm
Aleksander Holm edited on 4 Aug, 2020
Edits made to:
Infobox (--1 properties)
Infobox
B2X
B2B
Edits on 17 Jul, 2020
Henry Ogolla
Henry Ogolla approved a suggestion from Golden's AI on 17 Jul, 2020
Edits made to:
Article (+12/-12 characters)
Article

In September 2018, Oxford Genetics and ERS GenomicsERS Genomics extended their pre-existing non-exclusive, license agreement for the use of CRISPR gene editing technology. The agreement, which previously allowed Oxford Genetics to supply CRISPR modified cell lines to the US and Europe, has been extended to include the Asia Pacific region.

Golden AI"Funding autocalculation"
Golden AI edited on 17 Jul, 2020
Edits made to:
Infobox (+1 properties)
Infobox
Total funding amount (USD)
8,227,288
Edits on 15 Nov, 2019
Golden AI
Golden AI edited on 15 Nov, 2019
Edits made to:
Infobox (+1 properties)
Infobox
Investors
Mercia Fund Management
Edits on 17 Sep, 2019
Julius John Villarisco
Julius John Villarisco approved a suggestion from Golden's AI on 17 Sep, 2019
Edits made to:
Article (+6/-6 characters)
Article

On March 28, 2019 Oxford Genetics completed their series A funding round with £6.5 million in funding from Canaccord Genuity Limited, Invesco Asset Management Limited, and MericaMerica. The CEO and founder of Oxford Genetics, Ryan Cawood, made the following statement following the companies successful series A funding round:

Julius John Villarisco
Julius John Villarisco approved a suggestion from Golden's AI on 17 Sep, 2019
Edits made to:
Article (+12/-12 characters)
Article
This significant investment round will enable Oxford Genetics to further secure its market-leading position in the expanding fields of CRISPR, gene therapygene therapy and antibody engineering.
Jude Gomila
Jude Gomila edited on 17 Sep, 2019
Edits made to:
Article (+10/-10 characters)
Article

In August 2018, Oxford Genetics secured a $9.6m investment. The investment comes from existing investor Mercia Technologies PLC and Invesco Perpetua.lPerpetual. A spokesperson from Oxford Genetics made the following statement regarding the investment:

Edits on 16 Sep, 2019
Golden AI
Golden AI edited on 16 Sep, 2019
Edits made to:
Infobox (+1 properties)
Infobox
Funding rounds
Oxford Genetics funding round, March 28, 2019
Dawson Sewell
Dawson Sewell edited on 16 Sep, 2019
Edits made to:
Article (+1108/-150 characters)
Article

In August 2018, Oxford Genetics secured a $9.6m investment. The investment comes from existing investor Mercia Technologies PLC and Invesco Perpetua.l

License agreement
...
Funding
Growth

In August 2018, Oxford Genetics secured a $9.6m investment. The investment comes from existing investor Mercia Technologies PLC and Invesco Perpetua.l A spokesperson from Oxford Genetics made the following statement regarding the investment:

This will allow us to continue to exeed regulatory requirements and provide quality assurance for our clients. We will also add more analytical, purification and process development equipment, for instance small scale bioreactors, to enable us to fully support our clients from research up to the point of GMP bioproduction.
Series A

On March 28, 2019 Oxford Genetics completed their series A funding round with £6.5 million in funding from Canaccord Genuity Limited, Invesco Asset Management Limited, and Merica. The CEO and founder of Oxford Genetics, Ryan Cawood, made the following statement following the companies successful series A funding round:

This significant investment round will enable Oxford Genetics to further secure its market-leading position in the expanding fields of CRISPR, gene therapy and antibody engineering.

Edits on 15 Sep, 2019
Julius John Villarisco
Julius John Villarisco approved a suggestion from Golden's AI on 15 Sep, 2019
Edits made to:
Article (+2/-2 characters)
Article

In September 2018, Oxford Genetics and ERS Genomics extended their pre-existing non-exclusive, license agreement for the use of CRISPR gene editing technology. The agreement, which previously allowed Oxford Genetics to supply CRISPR modified cell lines to the USUS and Europe, has been extended to include the Asia Pacific region.

Edits on 9 Sep, 2019
Dawson Sewell
Dawson Sewell edited on 9 Sep, 2019
Edits made to:
Infobox (+1 properties)
Infobox
Industry
Synthetic biology
Edits on 12 Jun, 2019
Golden AI
Golden AI edited on 12 Jun, 2019
Edits made to:
Infobox (+1 properties)
Infobox
Funding rounds
Oxford Genetics seed round
Edits on 25 Apr, 2019
Golden AI
Golden AI edited on 25 Apr, 2019
Edits made to:
Infobox (+1 properties)
Infobox
Industry
Research
Edits on 11 Apr, 2019
Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 11 Apr, 2019
Edits made to:
Infobox (+1 properties)
Infobox
Industry
Biotechnology
Edits on 19 Mar, 2019
Golden AI
Golden AI edited on 19 Mar, 2019
Edits made to:
Infobox (+1 properties)
Infobox
Is a
Company
Edits on 14 Nov, 2018
Melanie Manipula"Approved suggestion from source: https://www.oxfordgenetics.com/"
Melanie Manipula approved a suggestion from Golden's AI on 14 Nov, 2018
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 14 Nov, 2018
Jude Gomila"Approved suggestion from source: https://www.oxfordgenetics.com/"
Jude Gomila approved a suggestion from Golden's AI on 14 Nov, 2018
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 26 Oct, 2018
Carla Faraguna
Carla Faraguna approved a suggestion from Golden's AI on 26 Oct, 2018
Edits made to:
Article (+18/-18 characters)
Article

In August 2018, Oxford Genetics secured a $9.6m investment. The investment comes from existing investor Mercia Technologies PLC and Invesco Perpetua.lInvesco Perpetua.l

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.